On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 52:49 Idebenone Clinical Trials in Duchenne (March 2017) 8 years ago Research & Clinical Trial Webinars,Webinars 44:38 NS Pharma’s Exon 53 Skipping Program: Trial Recruitment & Update (February 2017) 8 years ago Research & Clinical Trial Webinars,Webinars 39:37 MoveDMD Trial: Catabasis Provides Update (February 2017) 8 years ago Research & Clinical Trial Webinars,Webinars 41:31 Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017) 8 years ago Research & Clinical Trial Webinars,Webinars 58:17 Summit’s Utrophin Modulation Program (January 2017) 8 years ago Research & Clinical Trial Webinars,Webinars 1:00:21 Vamorolone (VBP15) Clinical Trials in Duchenne (January 2017) 8 years ago Research & Clinical Trial Webinars,Webinars 1:04:29 A Closer Look at the Potential of CRISPR/Cas9 in Duchenne (December 2016) 8 years ago Research & Clinical Trial Webinars,Webinars gene therapy 43:10 NS Pharma’s Exon 53 Skipping Program (November 2016) 8 years ago Research & Clinical Trial Webinars,Webinars «1…1718192021…25»Page 19 of 25
by: Parent Project Muscular Dystrophy
